Fresh analysis reveals that patients who discontinue new slimming jabs like Mounjaro or Wegovy tend to recover reduced body mass at a significantly accelerated pace than those who stop traditional diet and exercise plans.
Published data in a prominent health publication shows that while overweight people often shed substantial amounts of their total mass while using the jabs, the mass returns at an estimated rate of nearly a kilo each month upon discontinuation.
"Users purchasing such drugs should be cognizant of the danger of quick rebound weight gain when the medication is stopped," stated researcher Dr. Susan Jebb.
Such speed of recovery suggests a return to original weight within about a year and a half.
Analyzing Therapies
The analysis, which reviewed dozens of trials involving thousands of patients, compared the results of the injectable medications with conventional dieting.
Scientists note that individuals who lose weight through lifestyle changes alone usually see a more gradual weight regain—perhaps 0.1 kg a month—after stopping.
Explaining the Quick Regain
Nutrition scientists suggest the mode of action of the jabs accounts for the accelerated regain.
The injections imitate a body's own chemical called GLP-1, which helps regulate hunger.
"Sustained high doses of GLP-1 concentrations far above than the body's typical production may cause the body to generate a reduced amount of its endogenous hormone, and could lessen responsiveness to its effects," explained Dr. Adam Collins, a nutrition expert.
"Stopping of this hormone supplement leads to hunger is unsuppressed, making overeating much more probable."
An Ongoing Disease?
The NHS advise the jabs for individuals with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
A number of clinicians say that, given the high risk of relapse, the treatment is often ongoing.
This perspective is supported by drug manufacturers, who note that the findings "underscore the long-term nature of obesity," akin to managing diseases like diabetes.
User Experiences
Users who have stopped the jabs describe a powerful return of appetite.
"I experienced a switch activating and you're instantly ravenous," recalled one woman.
This difficulty is compounded if patients have not developed sustainable lifestyle or habit changes during therapy.
Widespread Interest
Survey data indicate that a significant number of adults in the UK have tried these injections in the last 12 months, with demand continuing to grow.
- Use is more common among women compared to men.
- The middle-aged age group shows the highest level of interest.
- Many obtain the medications through private healthcare rather than the NHS.
In conclusion, researchers emphasize that while GLP-1 drugs are potent tools for shedding pounds, they are not a permanent fix and long-term success relies on ongoing behavioural management.